Constance Cirrincione
Duke University
87 Papers
747 Citations
Constance Cirrincione is an academic researcher from Duke University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 44, co-authored 86 publications. Previous affiliations of Constance Cirrincione include Memorial Sloan Kettering Cancer Center & University of Texas MD Anderson Cancer Center.
Chat about Author
Papers
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
I. Craig Henderson,Donald A. Berry,George D. Demetri,Constance Cirrincione,Lori J. Goldstein,Silvana Martino,James N. Ingle,M. Robert Cooper,Daniel F. Hayes,Katherine Tkaczuk,Gini F. Fleming,James F. Holland,David B. Duggan,John T. Carpenter,Emil Frei,Richard L. Schilsky,William C. Wood,Hyman B. Muss,Larry Norton +18 more
TL;DR: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.
1.3K
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Kevin S. Hughes,Lauren Schnaper,Jennifer R. Bellon,Constance Cirrincione,Donald A. Berry,Beryl McCormick,Hyman B. Muss,Barbara L. Smith,Clifford A. Hudis,Eric P. Winer,William C. Wood +10 more
TL;DR: With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains, however, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation.
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
Kevin S. Hughes,Lauren Schnaper,Donald A. Berry,Constance Cirrincione,Beryl McCormick,Brenda Shank,Judith Wheeler,Lorraine A. Champion,Thomas J. Smith,Barbara L. Smith,Charles L. Shapiro,Hyman B. Muss,Eric P. Winer,Clifford A. Hudis,William C. Wood,David J. Sugarbaker,I. Craig Henderson,Larry Norton +17 more
TL;DR: Lumpectomy plus adjuvant therapy with tamoxifen alone is a realistic choice for the treatment of women 70 years of age or older who have early, estrogen-receptor-positive breast cancer.
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov,Donald A. Berry,Charles M. Perou,Baljit Singh,Constance Cirrincione,Sara M. Tolaney,Charles S. Kuzma,Timothy J. Pluard,George Somlo,Elisa Port,Mehra Golshan,Jennifer R. Bellon,Deborah Collyar,Olwen Hahn,Lisa A. Carey,Clifford A. Hudis,Eric P. Winer +16 more
TL;DR: In stage II to III TNBC, addition of either carboplatin or bevacizumab to NACT increased pCR rates, but whether this will improve relapse-free or overall survival is unknown.
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial
Ellen M. Lavoie Smith,Herbert Pang,Constance Cirrincione,Stewart B. Fleishman,Electra D. Paskett,Tim A. Ahles,Linda R. Bressler,Camilo E. Fadul,Chetaye Knox,Nguyet Le-Lindqwister,Paul Gilman,Charles L. Shapiro,Charles L. Shapiro +12 more
TL;DR: Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain, and the primary hypothesis was that dulOxetine would be more effective than placebo in decreasing chemotherapy- induced peripheral neuropathic pain.
931